Gamida Cell Ltd. stock is down -53.91% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 PUT. 100% of analysts rate it a buy.
Gamida Cell Ltd. develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk malignancies, as well as in Phase I/II clinical trials.